Par Health clinical trials
The registry lists 41 studies whose lead sponsor is Par Health or one of 3 companies grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2017.
Our grouping of 3 registry names, not the registry’s. See them and correct one ↓
- 41studies on the registry
- 0open to participants now
What it is testing
The drugs Par Health’s studies test, most studies first; none is open now — 23 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 5
- 0 open · 4
- Megestrol2 in phase 30 open · 3
- Megestrol Acetate2 in phase 30 open · 3
- 0 open · 2
- 0 open · 2
- Ciprofloxacin2 in phase 30 open · 2
- 0 open · 2
- 0 open · 2
- 0 open · 2
Show 13 moreShow fewer
- 0 open · 2
- 0 open · 2
- 0 open · 2
- 0 open · 1
- Dexamethasone1 in phase 30 open · 1
- Diclofenac1 in phase 30 open · 1
- 0 open · 1
- Lubiprostone1 in phase 30 open · 1
- 0 open · 1
- pimecrolimus1 in phase 30 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
All 41 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 11
- 12
- 413
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 33 started before 2011. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Par Health.
- Par Pharmaceutical, Inc.36 studies →Acquired — became part of Par Health, Nov 10, 2025 · source ↗
Something wrong?
- JHP Pharmaceuticals LLC3 studies →Acquired — became part of Par Health, Nov 10, 2025 · source ↗
Something wrong?
- Anchen Pharmaceuticals, Inc2 studies →Acquired — became part of Par Health, Nov 10, 2025 · source ↗
Something wrong?
Focus areas
Conditions Par Health leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 41 of 41.
- Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic DermatitisCompletedNCT03297502Phase 3
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed ConditionsCompletedNCT00652873Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed ConditionsCompletedNCT00652730Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed ConditionsCompletedNCT00652704Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed ConditionsCompletedNCT01380496Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Leflunomide Tablets Under Fed ConditionsCompletedNCT00653003Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy TubesTerminatedNCT01994642Phase 3
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Propranolol Under Fed ConditionsCompletedNCT00652600Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Tramadol/APAP Tablets Under Fed ConditionsCompletedNCT00652821Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis ExternaTerminatedNCT01910155Phase 3
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated SuspensionTerminatedNCT00637403Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer PatientsTerminatedNCT00637728Phase 3
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated SuspensionTerminatedNCT00637806Phase 3
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Equivalence Study of Specificity of PPDStatus unknownNCT01798095Phase 2
Sponsor listed in the registry: JHP Pharmaceuticals LLC · First submitted before JHP Pharmaceuticals LLC became part of Par Health
- Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard (PPD-S2)Status unknownNCT01798121Phase 2
Sponsor listed in the registry: JHP Pharmaceuticals LLC · First submitted before JHP Pharmaceuticals LLC became part of Par Health
- Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)Status unknownNCT01689831Phase 2
Sponsor listed in the registry: JHP Pharmaceuticals LLC · First submitted before JHP Pharmaceuticals LLC became part of Par Health
- Evaluation of Clinical Equivalence Between Two Lubiprostone ProductsCompletedNCT01372423Phase 3
Sponsor listed in the registry: Anchen Pharmaceuticals, Inc · First submitted before Anchen Pharmaceuticals, Inc became part of Par Health
- Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%CompletedNCT01456611Phase 3
Sponsor listed in the registry: Anchen Pharmaceuticals, Inc · First submitted before Anchen Pharmaceuticals, Inc became part of Par Health
- A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food StudyCompletedNCT01380431Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting ConditionsCompletedNCT01380457Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Metronidazole Capsules Under Fed ConditionsCompletedNCT01380522Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Metronidazole Capsules Under Fasting ConditionsCompletedNCT01380509Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fasting ConditionsCompletedNCT01380483Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Comparative Bioavailability Study of Lisinopril Tablets, 10 mgCompletedNCT01375244Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Torsemide Tablets Under Fasting ConditionsCompletedNCT00653549Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting ConditionsCompletedNCT00659074Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting ConditionsCompletedNCT00659685Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed ConditionsCompletedNCT00653458Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Torsemide Tablets Under Fed ConditionsCompletedNCT00654043Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting ConditionsCompletedNCT00654277Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Tramadol/APAP Tablets Under Fasting ConditionsCompletedNCT00653315Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Propranolol Under Fasting ConditionsCompletedNCT00653120Phase 2
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting ConditionsCompletedNCT00653380Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Leflunomide Tablets Under Fasting ConditionsCompletedNCT00652665Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Oxandrolone Tablets Under Fasting ConditionsCompletedNCT00652886Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Clonazepam ODT Under Fasting ConditionsCompletedNCT00652912Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Clonazepam Tablets Under Fasting ConditionsCompletedNCT00652639Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting ConditionsCompletedNCT00653055Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting ConditionsCompletedNCT00652795Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting ConditionsCompletedNCT00653419Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting ConditionsCompletedNCT00653393Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health